Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GTXI - GTx Inc.

Previous close
1.2
1.200   100.000%

Share volume: 0
Last Updated: Fri 07 Jun 2019 10:00:00 PM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 34%
Dept financing 7%
Liquidity 25%
Performance 27%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$1.20
P/E Ratio 
N/A
DAY RANGE
$1.20 - $1.20
EPS 
-$1.29
52 WEEK RANGE
$0.74 - $25.60
52 WEEK CHANGE
-$93.78
MARKET CAP 
28.862 M
YIELD 
N/A
SHARES OUTSTANDING 
24.052 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$10,542,044
AVERAGE 10 VOLUME 
$697,055
AVERAGE 30 VOLUME 
$294,780
Company detail
CEO: Marc Steven Hanover
Region: US
Website: http://www.gtxinc.com
Employees: 21
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

Recent news